MiMedx Group, Inc. (MDXG) Reports Full-year 2011 Financial Results
MiMedx Group, an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today announced its financial results for the year ended December 31, 2011. The company reported record revenue for full-year 2011 at $7.8 million, a tenfold increase over 2010 full-year revenue of $789,000. MiMedx reported a net loss of $10.2 million, or $(0.14) per diluted common share, for the year ended December 31, 2011, as compared to the net loss of $11.4 million, or $(0.19) per diluted common share, recorded for the year ended December 31, 2010. Adjusted EBITDA for the…